Helix News and Research

RSS

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Developments in nanotechnology and nanorobotics are opening up the prospects for nanomedicine and regenerative medicine where informatics and DNA computing can become the catalysts enabling health care applications at sub-molecular or atomic scales. While nanomedicine promises a new exciting frontier for clinical practice and biomedical research, issues involving cost-effectiveness studies, clinical trials and toxicity assays, drug delivery methods, and the implementation of new personalized therapies still remain challenging.

18 Mar 2010

NHI announces purchase/leaseback transactions

National Health Investors, Inc. announced today a total of $29.7 million in purchase/leaseback transactions. The transactions include three assisted living and memory care facilities totaling 102 units in Minnesota with Suite Living Senior Specialty Services (formerly known as Comforts of Home) for $17.2 million and a 66-bed acute psychiatric hospital known as Alvarado Parkway Behavioral Institute in La Mesa, California with Helix Healthcare for $12.5 million.

12 Mar 2010

Helix BioMedix enters into distribution agreement with RubyDerm Bio

Helix BioMedix, Inc., a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.

11 Mar 2010

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Helix BioPharma Corp. today announced financial results for the second quarter ended January 31, 2010.

10 Mar 2010

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

Helix BioMedix, Inc., a developer of bioactive peptides, announced additional funding in the amount of $2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.

10 Mar 2010

NovoStent receives CE Mark for SAMBA Stent and Delivery System for treatment of PAD

NovoStent® Corporation, a privately held medical device company, today announced that it has received CE Mark for its SAMBATM Stent and Delivery System for the treatment of peripheral artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of strength, flexibility and vessel coverage.

2 Mar 2010

Ion Torrent to award two Ion Personal Genome Machine sequencers through grant program

Ion Torrent™ today announced that it will award two Ion Personal Genome Machine (PGM™) sequencers in April 2010 through a grant program designed to help make DNA sequencing accessible to all scientists.

24 Feb 2010

Mechanism by which Plasmodium replicates itself in human blood to spread disease identified

Malaria remains one of the most deadly infectious diseases. Yet, how Plasmodium, the malaria parasite, regulates its infectious cycle has remained an enigma despite decades of rigorous research.

19 Feb 2010

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.

14 Feb 2010

Study: New mechanism may allow bacteria to develop resistance to antibiotics

Scientists have shown that cells' DNA-reading machinery can skim through certain kinds of damaged DNA without skipping any letters in the genetic "text." The studies, performed in bacteria, suggest a new mechanism that can allow bacteria to develop resistance to antibiotics.

10 Feb 2010

Greg Morgan awarded the Derek Price/Rod Webster Prize

Greg Morgan, an Associate Professor of Philosophy at Stevens Institute of Technology, was recently awarded the Derek Price/Rod Webster Prize for best paper of 2009 in History of Science by the History of Science Society.

28 Jan 2010

Unveiling of soybean genome could help boost crop yields in future

"Scientists on Wednesday unveiled the genome of the soybean, saying it was an achievement that should deepen understanding of one of the world's most important crops, help to boost yields and defend the plant against pests," Agence France-Presse reports. The study, published in the journal Nature, details the findings of the "[e]ighteen organisations, most of them American, [who] teamed up in a 15-year endeavour that yielded a draft of 85 percent of the soybean's 1.1 billion base pairs, the 'rungs' in the double-helix ladder of DNA," the news service writes

18 Jan 2010

CSHL scientists explain how initiation of DNA replication is coordinated and controlled by kinase proteins

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.

8 Jan 2010

Researchers discover rules that dictate the three-dimensional shapes of RNA molecules

University of Michigan researchers have discovered the rules that dictate the three-dimensional shapes of RNA molecules, rules that are based not on complex chemical interactions but simply on geometry.

8 Jan 2010

Gene's role in immune system may suggest new treatments for childhood asthma

Pediatric researchers have identified a novel gene involved in childhood asthma, in one of the largest gene studies to date of the common respiratory disease. Because the gene, called DENND1B, affects cells and signaling molecules thought to be instrumental in the immune system overreaction that occurs in asthma, the discovery may have singled out an important target for new treatments.

23 Dec 2009

First-quarter fiscal 2010 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the first quarter ended October 31, 2009.

9 Dec 2009

Protein plays a key role in cancer and DNA repair

A protein that plays a key role in copying DNA also plays a vital role in repairing breaks in it, UC Davis scientists have found. The work is helping researchers understand how cancer cells can resist radiation and chemotherapy, as well as how cells become cancerous in the first place.

4 Dec 2009

New study utilizes solid-state NMR spectroscopy to analyze intact bone

A new study using solid-state NMR spectroscopy to analyze intact bone paves the way for atomic-level explorations of how disease and aging affect bone.

3 Dec 2009

U.S. Patent Office approves multiple patent claims from Helix BioMedix

Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, “Short Bioactive Peptides for Cellular and Immunological Modulation,” covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.

20 Nov 2009

Alzheimer's disease research draws national attention

Research that is targeting the early diagnosis of Alzheimer disease has drawn national attention to the work of Michael Seidenberg, PhD, a faculty member at Rosalind Franklin University of Medicine and Science.

10 Nov 2009